Quest Diagnostics Inc SEC Filings

Quest Diagnostics (DGX) reported higher Q3 2025 results. Net revenues rose to $2,816 million from $2,488 million a year ago, and diluted EPS increased to $2.16 from $1.99. Operating income grew to $386 million, while net income attributable to Quest reached $245 million. Cost of services and SG&A increased alongside revenue growth, and Q3 included $11 million of restructuring and impairment charges.

For the first nine months of 2025, revenue was $8,229 million and diluted EPS was $6.57. Operating cash flow was strong at $1,421 million, funding $369 million of capex, $263 million of dividends, and $150 million of share repurchases (0.9 million shares). Cash ended at $432 million; total assets were $16,197 million and stockholders’ equity was $7,295 million.

DGX repaid $600 million notes that matured in March 2025 and extended its $750 million revolver to April 2030, with a $500 million accordion. The company closed the purchase of select Spectra Laboratories clinical testing assets for $34 million and finalized LifeLabs purchase accounting. As of October 15, 2025, shares outstanding were 111,242,362.

Director Timothy M. Ring reported a non‑derivative change related to deferred compensation in Quest Diagnostics (DGX). On 10/01/2025 he received an accrual of 233 phantom stock units under the company’s Amended and Restated Deferred Compensation Plan for Directors; these units convert to cash payable upon his termination of service as a director. The filing shows 17,036.495 phantom stock units credited in his deferred compensation account as of the transaction date, which includes units from dividend reinvestment transactions exempt from reporting. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. No option exercises, cash purchases, or sales of common stock are reported in this filing.

Wright L. Lassiter III, a director of Quest Diagnostics Inc. (DGX), reported on Form 4 that on 10/01/2025 he received 157 phantom stock units under the company's deferred compensation plan for directors. These phantom units arose from elective deferrals of the director's cash compensation and are payable in cash when the reporting person leaves board service. The filing states the total phantom stock units accrued in his deferred compensation account as of the transaction date include dividend-reinvestment credits exempt from separate reporting. The Form 4 shows zero dollar price for the transaction and indicates indirect ownership treatment for the accrued units.

Quest Diagnostics (DGX) Form 144 filing shows an insider planned sale and recent dispositions. The notice reports an intended sale of 227 common shares through Fidelity Brokerage with an aggregate market value of $42,706 and an approximate sale date of 09/26/2025. The 227 shares were acquired under an option (granted 02/19/2018) and will be paid in cash. The filer also reported two recent sales in the prior three months: 28,288 shares on 09/23/2025 for $5,293,312.79 and 175 shares on 09/24/2025 for $32,729.03. The filer attests not to possess undisclosed material adverse information.

Michael E. Prevoznik, Senior Vice President & General Counsel of Quest Diagnostics (DGX), reported option exercises and subsequent sales executed under a Rule 10b5-1 plan. On 09/23/2025 he exercised 28,288 non-qualified options at an exercise price of $103.57 and sold those 28,288 shares at a weighted-average price of $187.1222, leaving 38,117 shares beneficially owned after that transaction. On 09/24/2025 he exercised 175 options at $103.57 and sold 175 shares at a weighted-average price of $187.023, with total beneficial ownership remaining 38,117 shares. He also holds 5,691 shares indirectly in company retirement plans and retains outstanding options covering 28,288 and 175 shares that vested in installments beginning February 19, 2019.

Form 144 filed for Quest Diagnostics (DGX) reports a proposed sale of common stock and recent related transactions. The notice shows an intended sale of 175 shares through Fidelity Brokerage Services with an aggregate market value of $32,729 and an approximate sale date of 09/24/2025 on the NYSE. The 175 shares were acquired by option exercise on 09/24/2025 with cash payment. The filing also discloses a separate sale on 09/23/2025 by Michael Prevoznik of 28,288 common shares for gross proceeds of $5,293,312.79. The filer certifies no undisclosed material adverse information and references Rule 10b5-1 procedures.

Quest Diagnostics (DGX) filed a Form 144 notifying a proposed sale of 28,288 common shares through Fidelity Brokerage Services LLC on 09/23/2025 on the NYSE. The filing lists an aggregate market value of $5,293,313.43 and reports 111,823,441 shares outstanding, indicating the sale represents a very small fraction of total shares. The shares are reported as acquired under an option granted 02/19/2018 with acquisition and payment dated 09/23/2025 and payment in cash. The filer certifies they are unaware of undisclosed material adverse information and the notice contains the standard attestation language required by Rule 144.

Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported an insider sale under a Rule 10b5-1 plan. On 08/21/2025 he disposed of 1,975 shares of Quest Diagnostics common stock at $185 per share. Following the transaction, he beneficially owned 15,269 shares, held directly. The filing indicates the sale was executed pursuant to an established 10b5-1 trading plan and the Form 4 was signed by an attorney-in-fact on 08/25/2025. No derivative transactions or other securities were reported in this filing.

Quest Diagnostics (DGX) officer Patrick Plewman reported option exercise and a contemporaneous sale on 08/19/2025. He exercised 4,532 non-qualified stock options at an exercise price of $112.17 per share, resulting in ownership of 4,532 underlying shares. Immediately thereafter he sold 4,532 shares at $183.00 per share. After these transactions his beneficial ownership in the issuer is reported as 17,244 shares. The filings state the exercise and sale were executed pursuant to a Rule 10b5-1 sales plan and that the options vested in three annual installments between 2021 and 2023.